PCSK9[Biotinylated]-LDLR Binding Assay Kit
|Product Overview :||PCSK9 is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to the ectodomain of hepatic low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation.|
- Gene Information
- Related Products
|Size :||96 reactions|
|Applications :||Great for screening small molecules and antibodies that inhibit the binding of PCSK9 to LDLR ectodomain.|
|Storage :||Mixed storage conditions. Stable at least 12 months from date of receipt, when stored as directed|
|◆ Recombinant Protein|
|PCSK9-414R||Recombinant Rhesus macaque PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-86H||Active Recombinant Human PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-005H||Active Recombinant Human PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-406C||Recombinant Chinese hamster PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-407H||Recombinant Human PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-2775RCL||Recombinant Rhesus PCSK9 cell lysate||+Inquiry|
|PCSK9-2564MCL||Recombinant Mouse PCSK9 cell lysate||+Inquiry|
|PCSK9-2875HCL||Recombinant Human PCSK9 cell lysate||+Inquiry|
|◆ Assay kits|
|Kit-1806||PCSK9(D374T)-LDLR TR-FRET Assay Kit||+Inquiry|
|Kit-1808||PCSK9-LDLR TR-FRET Assay Kit||+Inquiry|
|Kit-0666||PCSK9-LDLR in vitro Binding Assay Kit||+Inquiry|
|Kit-0665||PCSK9-BIRC2 in vitro Binding Assay Kit||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.
PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.
This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.
Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.
Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.
PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.
Customer Reviews (0)Write a review
Ask a Question for All PCSK9 Products
Required fields are marked with *
My Review for All PCSK9 Products
Required fields are marked with *